Patients with rheumatoid arthritis (RA) tolerated a novel Janus kinase/Roh-associated protein kinase (JAK-ROCK) inhibitor without typical side effects. Phase 2 clinical trial at nine hospitals and ...
The reports suggest patients with rheumatoid arthritis (RA) could experience secondary neurological adverse events, though the side effect appears to be rare. A new report suggests patients who are ...
Finding the right medication for rheumatoid arthritis isn't easy, and a newer pill against the disease carries higher risks of heart attack, stroke and cancer than older RA drugs, a new clinical trial ...
In a single-arm RAMUS study, JAK inhibition with tofacitinib increased lower limb muscle volume without measurable strength ...
Patients with rheumatoid arthritis (RA) treated with Janus kinase (JAK) inhibitors showed no increased incidence of major adverse cardiovascular events (MACEs) compared with those treated with tumour ...
Please provide your email address to receive an email when new articles are posted on . JAK inhibition carried higher malignancy risk vs. biologic DMARDs. Malignancy risk was seen in older patients ...
PHILADELPHIA — Patients with rheumatoid arthritis frequently switched between JAK inhibitors in Australia, according to a presentation at ACR Convergence 2022. “JAK inhibitors and biologics are ...
A Janus kinase (JAK) inhibitor outperformed tumor necrosis factor (TNF) blockers for substantially reducing rheumatoid arthritis (RA) symptoms in patients for whom conventional anti-rheumatic drugs ...
MedPage Today on MSN
FDA Tweaks JAK Inhibitor Indication in Inflammatory Bowel Disease
The FDA updated the indication of the JAK inhibitor upadacitinib (Rinvoq) in inflammatory bowel disease (IBD) to account for ...
Newco Elevara Medicines Ltd. has raised $70 million in a series A to fund a phase IIa/IIb trial of ELV-001, a first-in-class, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback